MedTrace Logo

Pulse Endovascular ReperFUSION for Acute Ischemic Stroke

NCT06052969 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-08-07

No results posted yet for this study

Summary

Prospective, multi-center, single-arm early feasibility study enrolling a minimum of 15 subjects at up to a minimum of 3 active investigational sites in the United States.

The subjects must be diagnosed with acute ischemic stroke (AIS), must be post-mechanical thrombectomy, will have had intravenous thrombolytics, and have a visible MCA, ACA or PCA occlusive clot on initial angiographic imaging.

Each subject will receive the Pulse NanoMED procedure after attempted neurovascular therapy to achieve better reperfusion.

Conditions

  • Acute Ischemic Stroke AIS
  • Cerebral Arterial Disease

Interventions

DEVICE

Pulse NanoMED System

The Pulse NanoMED System is comprised of iron nanoparticles and a small, portable, magnetic Workstation.

Sponsors & Collaborators

  • Euphrates Vascular, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-01
Primary Completion
2026-03-15
Completion
2026-03-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06052969 on ClinicalTrials.gov